Please login to the form below

Not currently logged in
Email:
Password:

Alkermes to buy Elan unit

Alkermes is to acquire Elan's drug formulation and manufacturing unit for $960m, with company headquarters to be moved to Ireland

US-based Alkermes is to acquire Elan Drug Technologies (EDT) – Elan's unit for drug formulation and manufacturing – for a total of around $960m, creating the newly formed Alkermes plc to be based in Ireland.

The deal has been approved by company boards, with Elan to receive $500m in cash and 31.9 million ordinary shares of Alkermes plc common stock.

Existing shareholders of Alkermes will receive one share of the new Alkermes plc in exchange for each current share owned.

The company said the deal will enable Alkermes to become a sustainably profitable biopharmaceutical company specialising in developing treatments in the field of central nervous system (CNS).

Richard Pops, current chairman, president and CEO of Alkermes, will serve as Alkermes plc's chairman and CEO. Current head of Elan Drug Technologies, Shane Cook, will become president of Alkermes plc.

Pops said: "This merger will bring the scale and resources for strategic and balanced investment across the whole product continuum, from R&D innovation to clinical development, to world-class manufacturing and commercial expansion. We're looking forward to working with the EDT team to accelerate growth and to create value for our shareholders and the patients we serve."

Cooke also commented on the deal, reference the company's future product prospects: "With EDT's two recently approved drugs, Invega Sustenna (paliperidone palmitate – for schizophrenia) and Ampyra (dalfampridine – for multiple scleroris), driving revenue growth, the EDT business is an ideal complement to Alkermes' portfolio of approved and development-stage drug."

Elan has a webcast of a conference call concerning the deal.

9th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics